Loading clinical trials...
Loading clinical trials...
Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease
Conditions
Interventions
Avenciguat
Placebo
Locations
110
United States
Clearview Medical Research, LLC
Canyon Country, California, United States
Rancho Cucamonga Clinical Trials
Rancho Cucamonga, California, United States
Kidney & Hypertension Center
Victorville, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Nephrology Associates, P.A.
Newark, Delaware, United States
Indago Research and Health Center
Hialeah, Florida, United States
Start Date
April 27, 2021
Primary Completion Date
August 15, 2023
Completion Date
September 21, 2023
Last Updated
September 4, 2024
NCT07547098
NCT06278207
NCT07493642
NCT07241390
NCT05728216
NCT06926660
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions